pharmaceutical investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Blue Lagoon Secures $2 Million Line of Credit from Nicola Mining Enhancing Financial Flexibility Ahead of Production
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements